{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:49:34Z","timestamp":1791110974488,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0057523","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T22:02:23Z","timestamp":1362780143000},"page":"e57523","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":85,"title":["Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas"],"prefix":"10.1371","volume":"8","author":[{"given":"Jenny M.","family":"Kreahling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastou","family":"Foroutan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Razabdouski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn M.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Letson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soner","family":"Altiok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ludwig J, Trent JC (2008) Targeted Therapy in Sarcoma. In: Kurzrock RM M, editor. Targeted Cancer Therapy. Humana Press. 317\u2013329.","DOI":"10.1007\/978-1-60327-424-1_16"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"CD Blanke","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"T Helleday","year":"2008","journal-title":"Nature reviews Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1083\/jcb.134.4.963","article-title":"Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells","volume":"134","author":"P Jin","year":"1996","journal-title":"The Journal of cell biology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/emboj\/16.3.545","article-title":"Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation","volume":"16","author":"MJ O\u2019Connell","year":"1997","journal-title":"The EMBO journal"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-2-12","article-title":"Cdc25 and Wee1: analogous opposites?","volume":"2","author":"JA Perry","year":"2007","journal-title":"Cell division"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","article-title":"WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe","volume":"17","author":"PC De Witt Hamer","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref8","unstructured":"Merck Sharp &amp; Dohme Corp. aSoMC I (n.d.) Investigator\u2019s Brochure, MK-11775."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1073\/pnas.0609299104","article-title":"Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement","volume":"104","author":"TM Kiviharju-af H\u00e4llstr\u00f6m","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts","volume":"17","author":"V Rajeshkumar N","year":"2011","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1476-4598-8-34","article-title":"Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor","volume":"8","author":"S Mizuarai","year":"2009","journal-title":"Molecular cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil","volume":"9","author":"H Hirai","year":"2010","journal-title":"Cancer biology & therapy"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1535-7163.MCT-11-0529","article-title":"MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells","volume":"11","author":"JM Kreahling","year":"2012","journal-title":"Molecular cancer therapeutics"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1158\/1535-7163.MCT-06-0633","article-title":"H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation","volume":"6","author":"B Ewald","year":"2007","journal-title":"Molecular cancer therapeutics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/1535-7163.MCT-05-0425","article-title":"Low doses of cisplatin or gemcitabine plus Photofrin\/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299)","volume":"5","author":"E Crescenzi","year":"2006","journal-title":"Molecular cancer therapeutics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0360-3016(03)01443-3","article-title":"Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro","volume":"57","author":"B Pauwels","year":"2003","journal-title":"International journal of radiation oncology, biology, physics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1747-1028-6-21","article-title":"Novel insights into maintaining genomic integrity: Wee1 regulating Mus81\/Eme1","volume":"6","author":"Y Mart\u00edn","year":"2011","journal-title":"Cell division"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1","volume":"2","author":"M Aarts","year":"2012","journal-title":"Cancer discovery"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-009-0571-2","article-title":"Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome","volume":"122","author":"LM Murrow","year":"2010","journal-title":"Breast cancer research and treatment"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/annonc\/mdh073","article-title":"The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer","volume":"15","author":"T Yoshida","year":"2004","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"H Hirai","year":"2009","journal-title":"Molecular cancer therapeutics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/cbt.9.7.11276","article-title":"Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs","volume":"9","author":"P Indovina","year":"2010","journal-title":"Cancer biology & therapy"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1711720103","article-title":"p53 in tumour pathology: can we trust immunohistochemistry?","volume":"172","author":"PA Hall","year":"1994","journal-title":"\u2013Revisited! The Journal of pathology"},{"key":"ref24","first-page":"1342","article-title":"Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis","volume":"8","author":"P Lepelley","year":"1994","journal-title":"Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"key":"ref25","first-page":"2979","article-title":"Overexpression and mutation of p53 in epithelial ovarian cancer","volume":"51","author":"JR Marks","year":"1991","journal-title":"Cancer research"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/path.1711660402","article-title":"P53 in tumour pathology: can we trust immunocytochemistry?","volume":"166","author":"D Wynford-Thomas","year":"1992","journal-title":"The Journal of pathology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"AJ Levine","year":"1997","journal-title":"Cell"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1128\/MCB.8.2.531","article-title":"Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life","volume":"8","author":"CA Finlay","year":"1988","journal-title":"Molecular and cellular biology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-4827(91)90170-Y","article-title":"Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation","volume":"192","author":"S Kraiss","year":"1991","journal-title":"Experimental cell research"},{"key":"ref30","unstructured":"Fletcher CDM, Unni KK (2002) World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2407-11-156","article-title":"WEE1 inhibition sensitizes osteosarcoma to radiotherapy","volume":"11","author":"J PosthumaDeBoer","year":"2011","journal-title":"BMC cancer"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Schellens JH, Leijen S, Shapiro GI, Pavlick AC, Tibes R, <etal>et al<\/etal>.. (2009) A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. - ASCO. ASCO Annual Meeting.","DOI":"10.1200\/jco.2009.27.15_suppl.3510"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1535-7163.MCT-06-0388","article-title":"Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays","volume":"6","author":"B Rubio-Viqueira","year":"2007","journal-title":"Molecular cancer therapeutics"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.bjc.6604208","article-title":"G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer","volume":"98","author":"N Bucher","year":"2008","journal-title":"British journal of cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1152\/physrev.1996.76.2.593","article-title":"Transcriptional control of osteoblast growth and differentiation","volume":"76","author":"GS Stein","year":"1996","journal-title":"Physiological reviews"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Aubin JE (1998) Bone stem cells. Journal of cellular biochemistry Supplement 30\u201331: 73\u201382.","DOI":"10.1002\/(SICI)1097-4644(1998)72:30\/31+<73::AID-JCB11>3.0.CO;2-L"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jbmr.5650110612","article-title":"Development and characterization of a conditionally transformed adult human osteoblastic cell line","volume":"11","author":"V Bodine P","year":"1996","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1359\/jbmr.1997.12.2.179","article-title":"Establishment and characterization of conditionally immortalized stromal cell lines from a temperature-sensitive T-Ag transgenic mouse","volume":"12","author":"D Feuerbach","year":"1997","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/oxfordjournals.epirev.a036295","article-title":"Estrogen receptors and breast cancer","volume":"8","author":"JL Stanford","year":"1986","journal-title":"Epidemiologic reviews"},{"key":"ref40","first-page":"407","article-title":"The role of the androgen receptor in the development and progression of prostate cancer","volume":"26","author":"G Jenster","year":"1999","journal-title":"Seminars in oncology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.1982.tb07297.x","article-title":"Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?","volume":"51","author":"M Housset","year":"1982","journal-title":"British journal of haematology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(01)90002-2","article-title":"All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia","volume":"38","author":"P Fenaux","year":"2001","journal-title":"Seminars in hematology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"25297","DOI":"10.1074\/jbc.M201869200","article-title":"Activation of the phosphatidylinositol 3-kinase\/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells","volume":"277","author":"G L\u00f3pez-Carballo","year":"2002","journal-title":"The Journal of biological chemistry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0057523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T17:37:11Z","timestamp":1644514631000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0057523"}},"subtitle":[],"editor":[{"given":"Andrei L.","family":"Gartel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,8]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0057523","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,8]]}}}